Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer

Breast Cancer Research and Treatment

Volumn 119, Issue 2, 2010, Pages 315-323

  Jones, Robin L ^a   Salter, Janine ^a   A'Hern, Roger ^a   Nerurkar, Ash ^a   Parton, Marina ^a   Reis Filho, Jorge S ^b   Smith, Ian E ^a   Dowsett, Mitchell ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; ER; Neoadjuvant chemotherapy; Pathological complete response; Proliferation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; LOGISTIC MODELS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 74849113750     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0329-x     Document Type: Article

References (28)

1. RL Jones IE Smith 2006 Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response Lancet Oncol 7 869 874 10.1016/S1470-2045(06)70906-8 10.1016/S1470-2045(06)70906-8 1:CAS:528: DC%2BD28XhtVantb3M 17012049 (Pubitemid 44464080)
2. M Colleoni G Viale D Zahrieh, et al. 2004 Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 6622 6628 10.1158/1078-0432.CCR- 04-0380 10.1158/1078-0432.CCR-04-0380 1:CAS:528:DC%2BD2cXot1Oiu7o%3D 15475452 (Pubitemid 39346559)
3. G Pohl M Rudas S Taucher, et al. 2003 Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy Breast Cancer Res Treat 78 97 103 10.1023/A:1022165715043 10.1023/A:1022165715043 1:CAS:528:DC%2BD3sXntV2qsw%3D%3D 12611462 (Pubitemid 36223022)
4. AE Ring IE Smith S Ashley LG Fulford SR Lakhani 2004 Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 2012 2017 10.1038/sj.bjc.6602235 10.1038/sj.bjc.6602235 1:CAS:528:DC%2BD2cXhtVOjsLbL 15558072 (Pubitemid 40128767)
5. M Parton S Krajewski I Smith, et al. 2002 Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy Clin Cancer Res 8 2100 2108 1:CAS:528:DC%2BD38XmtVWitb0%3D 12114409
6. A Ravaioli L Bagli A Zucchini F Monti 1998 Prognosis and prediction of response in breast cancer: the current role of the main biological markers Cell Prolif 31 113 126 10.1111/j.1365-2184.1998.tb01190.x 10.1111/j.1365-2184.1998. tb01190.x 1:CAS:528:DyaK1MXhslCksA%3D%3D 9853425
7. CD Archer M Parton IE Smith, et al. 2003 Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer Br J Cancer 89 1035 1041 10.1038/sj.bjc.6601173 10.1038/sj.bjc.6601173 1:CAS:528: DC%2BD3sXntVKgurg%3D 12966422 (Pubitemid 37239208)
8. LA Carey EC Dees L Sawyer, et al. 2007 The triple negative paradox: primary tumour chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 10.1158/1078-0432.CCR-06-1109 10.1158/1078-0432.CCR-06-1109 1:CAS:528:DC%2BD2sXkt1enur0%3D 17438091 (Pubitemid 46698581)
9. RL Jones J Salter R A'hern, et al. 2008 The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer Breast Cancer Res Treat 10.1007/s10549-008-0081-7
10. RL Jones SR Lakhani AE Ring S Ashley G Walsh IE Smith 2006 Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma Br J Cancer 94 358 362 10.1038/sj.bjc.6602950 1:CAS:528:DC%2BD28XhtFGqs7c%3D 16421590 (Pubitemid 43237560)
11. P Ellis I Smith S Ashley, et al. 1998 Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer J Clin Oncol 16 107 114 1:STN:280:DyaK1c7gtFKrsg%3D%3D 9440730
12. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 10.1111/j.1365-2559. 1991.tb00229.x 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280: DyaK38%2FpvVSltw%3D%3D 1757079
13. JM Harvey GM Clark CK Osborne DC Allred 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474 1481 1:STN:280:DyaK1M3msFOjsA%3D%3D 10334533
14. T Petit M Wilt M Velten, et al. 2004 Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy Eur J Cancer 40 205 211 10.1016/S0959-8049(03)00675-0 10.1016/S0959-8049(03)00675-0 1:CAS:528:DC%2BD2cXjsVOlsA%3D%3D 14728934 (Pubitemid 38077022)
15. F Penault-Llorca A Cayre F Bouchet Mishellany, et al. 2003 Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome Int J Oncol 22 1319 1325 1:CAS:528:DC%2BD3sXksV2nsLw%3D 12739000
16. N Tinari R Lattanzio C Natoli, et al. 2006 Changes of topoisomerase II alpha expression in breast tumours after neoadjuvant chemotherapy predicts relapse-free survival Clin Cancer Res 12 1501 1506 10.1158/1078-0432.CCR-05-0978 10.1158/1078-0432.CCR-05-0978 1:CAS:528:DC%2BD28XitVGms7w%3D 16533774
17. E Arriola SM Rodriguez-Pinilla MB Lambros, et al. 2007 Topoisomerase II alpha amplification may predict benefit from adjuvant anthracycline in HER2 positive early breast cancer Breast Cancer Res Treat 106 181 189 10.1007/s10549-006-9492-5 10.1007/s10549-006-9492-5 1:CAS:528:DC%2BD2sXht1CgtL7M 17260090 (Pubitemid 350045015)
18. A Bottini A Berruti MP Brizzi, et al. 2005 Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial Endocr Relat Cancer 12 383 392 10.1677/erc.1.00945 10.1677/erc.1.00945 1:CAS:528:DC%2BD2MXnsl2ntbk%3D 15947110 (Pubitemid 40896453)
19. IF Faneyte JG Schrama JL Peterse PL Remijnse S Rodenhuis MJ van de Vijver 2003 Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 406 412 10.1038/sj.bjc.6600749 10.1038/sj.bjc.6600749 1:STN:280:DC%2BD3s%2FlvVChtA%3D%3D 12569384 (Pubitemid 36308152)
20. HB Prisack C Karreman O Modlich, et al. 2005 Predictive biological markers for response of invasive breast cancer to anthracycline/ cyclophosphamide-based primary (radio-)chemotherapy Anticancer Res 25 4615 4621 1:CAS:528:DC%2BD2MXhtlWgtL%2FF 16334152
21. C Liedtke C Mazouni KR Hess, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 8 1275 1281 10.1200/JCO.2007.14.4147 10.1200/JCO.2007.14.4147 18250347
22. R Rouzier CM Perou WF Symmans, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 16 5678 5685 10.1158/1078-0432.CCR-04-2421 10.1158/1078-0432.CCR-04-2421 1:CAS:528:DC%2BD2MXos1Cjs7k%3D 16115903 (Pubitemid 41170290)
23. M Takada A Kataoka M Toi, et al. 2004 A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer Int J Oncol 25 397 405 1:CAS:528:DC%2BD2cXmvF2ru74%3D 15254737
24. J Lee YH Im SH Lee, et al. 2008 Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer Cancer Chemother Pharmacol 61 569 577 10.1007/s00280-007-0506-8 10.1007/s00280-007-0506-8 1:CAS:528:DC%2BD1cXjsFWquw%3D%3D 17508214
25. A Vincent-Salomon A Rousseau M Jouve, et al. 2004 Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy Eur J Cancer 40 1502 1508 10.1016/j.ejca.2004.03.014 10.1016/j.ejca.2004.03.014 1:CAS:528:DC%2BD2cXkvVCmu7s%3D 15196533 (Pubitemid 38757737)
26. AH Honkoop PJ van Diest JS de Jong, et al. 1998 Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer Br J Cancer 77 621 626 1:STN:280:DyaK1c7ktlenuw%3D%3D 9484820
27. H Bonnefoi S Diebold-Berger P Therasse, et al. 2003 Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 14 406 413 10.1093/annonc/mdg108 10.1093/annonc/mdg108 1:STN:280:DC%2BD3s%2Fos1Gmtw%3D%3D 12598346 (Pubitemid 36367418)
28. E de Azambuja F Cardoso G de Castro Jr, et al. 2007 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients Br J Cancer 96 10 1504 1513 10.1038/sj.bjc.6603756 10.1038/sj.bjc.6603756 17453008 (Pubitemid 46762956)